SCHEMBL3726705

SCHEMBL3726705

CCOC(=N)Cc1ccccc1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TSHR P16473 3/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C19 P33261 1/20 0.48
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
MAPT P10636 2/20 0.45
PLIN1 O60240 1/20 0.45
POLB P06746 1/20 0.45
PLIN5 Q00G26 1/20 0.45
ABHD5 Q8WTS1 1/20 0.45
IDO1 P14902 2/20 0.44
TAAR1 Q96RJ0 2/20 0.44
GLS O94925 1/20 0.44
CHRM2 P08172 1/20 0.43
CHRM1 P11229 1/20 0.43
TTR P02766 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6406497 0.98 LMNA (0.49) LMNASMN1; SMN2TSHRCYP1A2CYP3A4
Hydrochloric Acid SCHEMBL6860234 0.81 LMNA (0.51) LMNASMN1; SMN2TSHRKMT2AMEN1
SCHEMBL1792326 0.79 TSHR (0.55) LMNASMN1; SMN2TSHRCYP1A2CYP3A4
SCHEMBL23616865 0.79 LMNA (0.50) LMNASMN1; SMN2TSHRCYP1A2CYP3A4
Hydrochloric Acid SCHEMBL5340879 0.79 CTBP2 (0.41) SMN1; SMN2TSHRKMT2AMEN1MAPT
SCHEMBL7634089 0.77 KMT2A (0.54) LMNASMN1; SMN2TSHRCYP1A2CYP3A4
SCHEMBL12568942 0.77 LMNA (0.64) LMNASMN1; SMN2TSHRCYP1A2CYP3A4
Hydrochloric Acid SCHEMBL5338849 0.76 ALDH1A1 (0.44) LMNASMN1; SMN2KMT2AMEN1MAPT
Hydrochloric Acid SCHEMBL5342849 0.76 ALDH1A1 (0.44) LMNASMN1; SMN2CYP1A2CYP3A4CYP2D6
SCHEMBL7918109 0.75 HTT (0.41) CYP2D6KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2435435-B1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBVIE INC (US) 2014-01-29 EP disclosed
US-8536180-B2 Pyrimidine inhibitors of kinase activity ABBVIE INC. (US) 2013-09-17 US disclosed
CN-102459265-A Pyrimidine inhibitors of kinase activity ABBOTT LAB 2012-05-16 CN disclosed
WO-2010138575-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 WO disclosed
US-20100305118-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305118-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY IGF1R, TK1, CDK2 LMNA 1836/4885SMN1; SMN2 1475/4885TSHR 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.